

## Index

- acceptance and commitment therapy (ACT), 32  
 acetylfentanyl, 79–80, 84  
 acrylfentanyl, 79, 84  
 acute kidney injury, SCRA-related, 310  
 acute toxicity, factors linked to, 9  
 ADHD (attention deficit hyperactivity disorder)  
   amphetamine dependence and, 154  
   amphetamine treatment, 146  
   methamphetamine treatment, 203  
 agitation, benzodiazepine treatment, 51, 152, 181, 252, 254, 313, 314  
 akathisia, serotonin syndrome and, 151  
 alcohol  
   co-ingestion  
     amphetamine-type stimulants, 158  
     benzodiazepines, 67, 68, 70  
     cathinones, 245, 251  
     fentanyl, 84  
     GHB/GBL, 41, 43, 44, 45, 53  
       deaths related to, 40, 43  
     hallucinogens, 273  
     ketamine, 109–111, 117, 119  
     MDMA, 171, 174, 273  
       risks of, 179  
     mephedrone, 251  
       deaths related to, 251  
     nitrous oxide, 134  
     opioids, 84  
     SCRAs, 304, 310  
       lifetime use, 303  
   effects of masked by  
     methamphetamine, 210  
   HPPD triggered by, 282  
   MDMA, research on the use of for alcohol use disorder, 170  
   relapse prevention approach, 32  
   similarities in patterns of use with NPS, 23  
 Alcoholics Anonymous (AA), 31  
 amphetamines, 144  
   drug interaction with opiates, 84  
   effects on dopamine, 143  
   empathogenic effects, 165  
     *see also* entactogenic/empathogenic effects,  
     MDMA.  
     medical and other legitimate uses, 146  
     prevalence in northern and eastern Europe, 144  
 amphetamine-type stimulants (ATS), 146  
   acute toxicity, 148  
     diagnosis and assessment, 151  
     poly-drug use, 158  
     serotonin syndrome, 149–150, 153, 158  
     symptoms/features, 148–149  
   chronic harms  
     dependence and withdrawal, 153  
     diagnosis and assessment, 154  
     stepped care, 155–156  
     management, 154  
     physical and psychiatric/psychological harms, 153–154  
   effects, desired, 147  
   harm reduction advice, 158  
   high-risk injecting and sexual behaviours, 147–148  
   mortality, 148  
   pharmacology, 146  
   prevalence and patterns of use, 147  
   public health and safety, 158  
   routes/modes of ingestion and dosing frequency, 147  
   similarity to MDMA, 144  
   WHO definition, 146  
 antipsychotic medications  
   amphetamines and, 157–158  
   benzofuran compounds and, 188  
   GHB/GBL and, 40, 51  
   hallucinogens and, 280  
   ketamine and, 117  
   methamphetamines and, 211, 214, 216  
   SCRAs and, 313, 314  
   synthetic cathinones and, 252  
 anxiety, self-medication  
   GHB/GBL, 40  
   ketamine, 106  
   nitrous oxide, 133  
 arylcyclohexylamines, *see also* ketamine; methoxetamine (MXE), 102, 109, 111  
 attention deficit hyperactivity disorder, 203, *see* ADHD (attention deficit hyperactivity disorder).  
 autistic adults, MDMA-assisted psychotherapy study, 170  
 AV411 (ibudilast), 217  
 behavioural couples therapy (BCT), effectiveness in treatment of drug misuse, 32  
 benzodiazepine, treatment, agitation, 51, 152, 181, 252, 254, 313, 314  
 benzodiazepine misuse  
   outcomes associated with  
     concomitant opioid use, 68  
     poor outcomes associated with, 67  
   reasons for, 67–68  
 benzodiazepines, 65  
   acute harms, 68  
   acute toxicity  
     clinical management, 70  
     symptoms/features, 68  
   and aggressive behaviours, 70  
   availability to purchase, 66  
   clinical uses  
     agitation treatment, 51, 152, 181, 254, 313, 314  
     efficacy, 65  
     GHB/GBL withdrawal syndrome treatment, 50, 51  
     hallucinogen intoxication management, 279, 280  
     HPPD intervention, 283  
     ketamine toxicity treatment, 111  
     ketamine withdrawal management, 117  
     methoxetamine toxicity treatment, 112  
     SCRA intoxication management, 313  
     SCRA withdrawal treatment, 314  
   serotonin syndrome treatment, 152

- synthetic cathinone intoxication  
 treatment, 252
- synthetic cathinone withdrawal  
 management, 254
- dependence and withdrawal, 70–71  
 management, 71–72  
 management, Cochrane review, 72  
 symptoms/features, 70–71  
 treatment, 71
- effects of, 68
- emergence as recreational drugs, 66
- fatal toxicity index, 9
- half-life, 66
- half-life and duration of effects, 66
- and high-risk sexual behaviours, 69–70
- legal status, 65, 66
- mental health co-morbidity, 71
- methamphetamine come-down  
 management, 206
- misuse of as worldwide public health  
 concern, 65
- modes of use, 66–67
- mortality, 69
- most common, 66
- pharmacology, 65–66
- poly-drug use, 67
- population groups most likely to  
 misuse, 67–68
- potency, 66  
 comparison of NPS with  
 traditional benzodiazepines, 69
- prevalence and patterns of use, 67
- reasons for benzodiazepine misuse, 67–68
- reported adverse effects, 69
- reported hospital presentations and  
 overdoses, 69
- research evidence, 65
- risks, 68–69  
 co-ingestion with ketamine, 110
- street names, 65
- targeting of at long-term/  
 problematic drug users, 23
- testing, 70
- benzofurans  
 acute toxicity, 188  
 management, 189
- chronic harms, management, 189
- clinical uses, 188
- derivatives, 187
- effects  
 adverse, 277  
 desired, 188  
 empathogenic, 165  
 unwanted, 188
- fatal toxicity index, 9
- harm reduction advice, 189
- modes and patterns of use, 188
- pharmacology, 187, 277
- N-Benzylphenethylamines.
- N-Benzylpiperazin (BZP), 144
- beta-keto (bk) amphetamines, 144
- bingeing behaviour  
 hallucinogens, 272  
 ketamine, 112
- bipolar disorder, benzodiazepines and,  
 71
- blood–brain barrier permeability  
 amphetamine-type stimulants, 146  
 fentanyl, 80  
 GHB/GBL, 38  
 MDPV, 243  
 methamphetamine, 202  
 nitrous oxide, 131  
 synthetic cathinones, 242
- Bluelight, 8
- bodybuilding, use of GHB in, 38
- brachycardia, co-use of substances  
 and, 179
- brief interventions  
 extended, 29  
 WHO manual, 27
- British Association for  
 Psychopharmacology, 3
- bromo-dragonfly  
 adverse effects, 276  
 co-ingestion combinations, 273  
 effects, onset and duration, 272  
 toxicity, 275  
 adverse effects, 277
- buprenorphine, 85, 88  
 treatment of amphetamine and  
 methamphetamine  
 dependence with, 218
- bupropion  
 clinical uses, 243  
 synthetic cathinones contained in,  
 240  
 treatment of amphetamine and  
 methamphetamine  
 dependence with, 157, 217,  
 218, 221
- 1,4-butanediol, 37  
 GHB conversion process, 37  
 high anion gap metabolic acidosis  
 associated with intoxication,  
 42
- industrial use, 38
- metabolism blocked by ethanol and  
 fomepizole, 38
- butane, 134
- caffeine  
 adulteration of MDMA with,  
 166–167, 171  
 risks of co-intoxication with  
 MDMA, 179
- cannabis, co-ingestion  
 GHB/GBL, 39  
 hallucinogens, 273  
 methamphetamine, risks, 210
- cardiac disease, risks of nitrous oxide  
 use, 134
- carfentanyl, 79, 87
- catatonia, 109
- cathinone/cathine, legal status, 241
- cathinones, 6  
 empathogenic effects, 165  
 synthetic, *see* synthetic cathinones.
- CBD (cannabidiol), 300, 309
- chemsex  
 association with risk and adverse  
 effects, 8  
 concept of, 8, 209  
 deaths associated with, 40  
 drugs typically used, 8, 38–39, 40,  
 208  
 mephedrone, 7  
 methamphetamine, 208, 209  
 NPS use, 7, 30  
 role of in problematic GHB use,  
 40
- club drugs  
 concept and background, 1  
 definition, 4–6  
 overall use, 7  
 users and contexts of use, 7
- ‘clubbers’  
 mephedrone use, 244  
 methamphetamine use, 204
- cluster headaches, therapeutic  
 potential of LSD and  
 psilocybin, 274
- cobicistat, 44, 102, 210, 251
- cocaine  
 co-ingestion risks  
 MDMA, 179  
 methamphetamine, 210  
 dopamine reuptake action, 143  
 drug interaction with fentanyl, 84  
 fentanyls found in products sold as,  
 81  
 prevalence in western and southern  
 Europe, 144
- Cochrane reviews  
 amphetamine  
 dependence treatment, 218  
 psychosis treatment, 154, 158  
 benzodiazepine discontinuation, 72  
 CBT and CM approaches, 29  
 methamphetamine, 202  
 psychosocial interventions  
 cocaine and psychostimulant  
 amphetamine disorders, 215  
 stimulant use, 155
- codeine, methamphetamine and, 210
- cognitive behavioural therapy (CBT)

## Index

- for amphetamine-type stimulant-use disorders, 156
- benzodiazepine dependence  
 treatment, 72
- effectiveness of interventions based on, 29
- high-risk sexual behaviour  
 interventions, 220, 222
- methamphetamine and, 212, 215
- relapse prevention treatment, 32
- SMART groups, 31
- structured drug treatment, evidence for, 29
- substance-misusing MSM, 31
- third-wave models, 32
- cognitive-behavioural therapy (CBT)  
 high-risk sexual behaviours, 220
- relapse prevention treatment, 32
- coma/loss of consciousness, 41
- Commission on Narcotic Drugs, 6
- communication about drugs by users, 8–9
- community reinforcement approach (CRA), 22, 29, 32, 155
- structured drug treatment, evidence for, 29
- contingency management (CM)  
 concept, 32
- effectiveness of interventions based on, 29
- methamphetamine, dependence and withdrawal, 216
- methamphetamine and, 215, 216
- structured drug treatment, evidence for, 29
- control of NPS, legal, changes in, 6
- counterfeit medications, risks of using, 69
- cultural competence, role of in service engagement and uptake, 23, 40, 222
- CYP2B6 inhibitors, ketamine and, 102
- CYP2D6 inhibitors  
 examples of, 210
- GHB and, 44
- mephedrone and, 251
- methamphetamine and, 210
- CYP3A4 inhibitors  
 GHB and, 44
- ketamine and, 102
- mephedrone and, 251
- CYP450 inhibitors, ketamine and, 115
- cyproheptadine, serotonin syndrome management, 180
- ‘date rape’, GHB implicated in, 38
- death  
 amphetamine-type stimulants, 148
- benzodiazepines, 69
- increase in mortality risk, 67
- club drug and NPS-associated,  
 limited data, 12
- GHB/GBL-associated, 40
- hallucinogen-associated, 279
- ketamine-associated, 110
- MDMA-associated, 173–174
- methamphetamine-associated, 206
- methoxetamine-associated, 110
- nitrous oxide-associated, 133
- opioid-associated, 92
- benzodiazepines commonly implicated in, 68
- PMMA-associated, 177
- SCRA-associated, 305
- synthetic cathinone-associated, 251
- deep-vein thrombosis, injecting risk, 145, 254
- delta-9-tetrahydrocannabinol, 299, 312
- depression  
 ketamine  
 role of in treatment, 101, 103, 116
- self-medication with, 106
- methoxetamine, potential as treatment for, 103
- detoxification, CBT-based relapse prevention treatment following, 32
- dexamphetamine, treatment of  
 amphetamine and methamphetamine  
 dependence with, 157, 217
- dextromethorphan (DXM), 101, 105, 179
- diabetic ketoacidosis (DKA),  
 ketamine, chronic harms, 115
- diabetics  
 mephedrone, potential danger to people with, 250
- risks of ketamine use, 115
- risks of MDMA use, 179
- risks of synthetic cathinone use, 250
- dialectical behaviour therapy (DBT), 32
- diphenidine, 101, 102  
 acute toxicity, 110
- dissociative drugs, 101–102, *see also*  
 ketamine; methoxetamine (MXE); nitrous oxide (N<sub>2</sub>O), 20),
- dopamine  
 amphetamines and, 153
- amphetamine-type stimulants and, 153
- ketamine and, 102, 112
- MDMA and, 168, 178
- methamphetamine and, 213
- methoxetamine and, 102, 202
- methoxphenidine and, 110
- stimulants and, 143, 144
- synthetic cathinones and, 242–243, 249, 252
- driving  
 ketamine and, 119
- methamphetamine and, 222
- SCRA use and, 315
- drug acquisition, new markets for, 8–9
- drug dependence treatment, best practice principles, 13
- drug testing for club drugs and NPS, limitations of, 11–12
- drug treatment services  
 indicators for referral, 25
- as setting for higher-intensity PSIs, 25
- Drugs Forum, 8
- Early Warning Advisory on New Psychoactive Substances (UNODC), 1
- ecstasy  
 co-ingestion with GHB/GBL, 39
- see also* MDMA (ecstasy).
- effects/harms of club drugs and NPS, 9–12
- new generations of substances, 11
- toxicity and other acute harms, 9–10
- unpredictability, 10–11
- electro-acupuncture,  
 methamphetamine and, 217
- electroconvulsive therapy (ECT),  
 psychosis and, 216
- emergency department admissions/presentations  
 amphetamine users, 154
- butane mistaken for nitrous oxide, 134
- chemsex and, 208
- chest pain after methamphetamine use, 207
- GHB users, 41
- ketamine users, 107–109, 111
- MDMA users, 174, 180
- methamphetamine users, 207, 210–211, 213
- NPS and drug-related presentations, 12
- psychosis, 154, 314
- SCRA users, 302, 310, 312, 314
- synthetic cathinone users, 250, 252
- clinical assessment, 251
- emergency departments, as setting for lower-intensity PSIs, 25
- endocarditis, injecting risk, 145, 207, 254
- entactogenic/empathogenic effects  
 definition, 165
- difficulty of replicating, 165
- MDMA, 165
- pharmacology, 169

- role of serotonin, 143
- substances which produce, 165, 166, 245
- epilepsy, risks of nitrous oxide use, 134
- erectile dysfunction, 172, 204
- ergolines
  - adverse effects, 276
  - routes/modes of ingestion and dosing frequency, 273
- Erowid, 8
- European Drug Emergencies Network (Euro-DEN), 12
- 'excited delirium'
  - clinical management, 280
  - fatalities, 278
  - hallucinogens, 278
- exercise
  - methamphetamine use and, 216
  - potential for treatment of substance use disorder, 156
- exogenous obesity, methamphetamine treatment, 203
- facilitating access to mutual aid (FAMA), 31
- fentanyl
  - estimated lethal dose, 81
  - legal status, 78
- fentanyl NPS
  - acute toxicity, 9
  - see also* fentanyls.
- fentanyl-induced respiratory muscle rigidity (FIRMR), 82
- treatment, 86
- fentanyls
  - acetylfentanyl, 83
  - acrylfentanyl, 83
  - acute hams, 81–84
  - acute toxicity, naloxone treatment, 85
    - clinical settings, 85–86
    - community settings, 86–87
  - butyrylfentanyl, 83
  - carfentanyl, 83
  - chronic harms, 87–88
  - dangers of, 80, 82–84
  - dependence and withdrawal, 87–88
    - management, 88–89
  - effects
    - adverse, 81–84
    - desired, 81
    - long-term, 88
  - examples, 83
    - non-pharmaceutical fentanyl analogues, 79
  - 4-fluorobutyrylfentanyl, 83
  - furanylfentanyl, 83
  - legal status, 78
  - methylfentanyls, 83
  - mode and patterns of use, 80–81
- ocfentanil, 83
- overdose
  - atypical characteristics, 82
  - management, 87
- pharmacology, 79–80
- poly-drug use, 84–85
- risks of, 82, 84
- position on the illegal drug market, 79
- potency, 81, 84
- public health risks, 82, 88
- research evidence, 79
- risk of acute toxicity and overdose, 78
- testing limitations, 85
- toxicity comparison with heroin, 84
- withdrawal symptoms, 88
- festival attendees, adoption of dosing related harm reduction strategies by, 14
- flashbacks, hallucinogen related, *see also* hallucinogen persisting perception disorder (HPPD), 280–281
- 4-fluoroamphetamine (4FA), 167
- fluoxetine
  - MDMA and, 179
  - methamphetamine and, 210
- formal psychological treatment
  - benefits for service users completing detoxification, 31
  - competences required, 30
  - formulation-based approach, 30
  - higher-intensity PSIs, 29–31, 156
  - multiple-model perspective, 30
- FRAMES model of PSI, 27
- example, 28–29
- gamma-aminobutyric acid (GABA), 37, 65
- gamma-butyrolactone (GBL)
  - industrial use, 38
  - see also* GHB/GBL.
- gamma-hydroxybutyrate (GHB)
  - association with high-risk sexual behaviours, 39, 40
  - dose-dependent effects, 41
  - half-life, 37
  - hazard profile, 41
  - implication in crime, Hungarian study, 38
  - implication in 'date rape' and sexual assaults, 38, 40
  - precursors, 37
  - risks of co-ingestion with methamphetamine, 210
  - role in alcohol and opiate detoxification, 38
  - see also* GHB/GBL.
- gamma-hydroxyvaleric (GHV), 38
- gamma-hydroxyvaleric acid (GHV), 37
- gamma-valerolactone (GVL), 37, 38
- gender differences
  - MDMA
    - adverse effects, 175, 177
    - fatalities, 177
  - nitrous oxide effects, debate around, 133
  - stimulants, responses to, 157
- GHB/GBL
  - accidental overdoses, 41
  - acute harms, poly-drug use and drug interactions, 44
  - acute toxicity, 40–44
    - cardiovascular effects, 43
    - CNS and respiratory effects, 43
    - diagnosis and assessment, 45
    - neurological and psychiatric effects, 42
    - symptoms/features, 42–44
    - treatment outcome, 46
    - treatment outcome, London study, 46
    - vomiting, 43–44
  - association with sexual assault, 53
  - chronic harms, 47–53
    - dependence and withdrawal, 47–49
    - see also* GHB/GBL, withdrawal syndrome.
    - for men who have sex with men, 49
    - research recommendations, 49
  - clinical and other uses, 38
  - demographic and socio-economic perspective, 39
  - drugs commonly co-ingested with, 39
  - effects, desired and unwanted, 39–40
  - fatal toxicity index, 9
  - half-life, 41
  - high-risk sexual behaviours, 40, 49
  - legal status, 37
  - methamphetamine come-down management with, 206
  - mortality, 40
  - overdose
    - clinical management, 45–46
    - harm reduction measures, 46
  - pharmacology, summary, 37–38
  - prevalence and patterns of use, 38–39
  - psychosocial interventions, 50
  - public health and safety, 53
  - recreational use, 37
  - research evidence, 37
  - routes/modes of ingestion and dosing frequency, 39
  - withdrawal syndrome, 47–49
    - acute, 44, 46

## Index

- clinical management, 50–52  
 medications, 51  
 self-medication/detoxification, 51  
 identification and assessment, 50  
 medically assisted detoxification, 52  
 supporting recovery, 52–53  
 predictors, 47  
 rapid onset and duration, 47  
 symptoms, 38, 47, 48–49  
 persistence, 49  
 psychiatric symptoms, 49  
 variations and unpredictability, 48  
 Glasgow Coma Scale, 107  
 Global Drug Survey  
 on ketamine, 103  
 on nitrous oxide, 131  
*see also* World Drug Report.  
 gonorrhoea, 40  
 grapefruit juice, co-ingestion with  
 fentanyl, 84
- hallucinogen persisting perception  
 disorder (HPPD), 280–281  
 benzodiazepine intervention, 283  
 cannabinoids and, 309  
 comparison of type I and type II,  
 282–283  
 contested nature, 281  
 definitions, 281, 283  
 diagnosis and assessment, 281, 282  
 symptoms/features, 283  
 treatment, 283–284
- hallucinogens  
 acute toxicity, 275–280  
 adverse effects  
 ergolines, 276  
 phenethylamines, 276–277  
 physiological, 276–278  
 psychological/psychiatric, 278  
 clinical management, 280  
 psychosis, 278  
 trauma and self-injury, 278  
 tryptamines, 277–278  
 clinical management, 279–280  
 mortality, 279  
 symptoms/features, 275–279  
 chemical groups, 267  
 chronic harms, 280–284  
 brain imaging studies, 280  
 dependence and withdrawal, 280  
 HPPD, 280–284  
*see also* hallucinogen persisting  
 perception disorder (HPPD).  
 psychosocial interventions, 284  
 clinical uses, research on, 270  
 effects  
 adverse, 276–279  
 desired, 273–274  
 onset and duration, 271–272  
 unwanted, 274–275  
 harms associated with newer  
 generations of, 11  
 legal status, 267–269  
 pharmacology, 269–270  
 lysergamides, 268  
 phenethylamines, 268–269  
 tryptamines, 268  
 poly-drug use, 273  
 potency, 271  
 prevalence and patterns of use,  
 270–271  
 micro-dosing, 271  
 research evidence, 269  
 routes/modes of ingestion and  
 dosing frequency, 271–273  
 ergolines, 273  
 phenethylamines, 273  
 tryptamines, 272  
 self-medication uses, 274  
 terminology, 267  
 therapeutic effects, 274
- haloperidol  
 MDMA and, 179, 181  
 methamphetamine and, 210
- harm reduction measures/advice  
 adoption by festival attendees, 14  
 amphetamine-type stimulants, 158  
 benzofurans, 189  
 club drug and NPS use, 13–14  
 GHB/GBL overdose, 46  
 ketamine, 119  
 MDMA, 186–187  
 methamphetamine, 222  
 nitrous oxide, 137  
 SCRAs, 315  
 synthetic cathinones, 254
- hepatitis C  
 cognitive impairment and, 215  
 injecting risk  
 amphetamine-type stimulants,  
 148  
 fentanyls, 88  
 synthetic cathinones, 145, 250  
 methamphetamine use, association  
 with, 208, 213
- heroin  
 comparison of fentanyl with, 81  
 overdose, 81, 87  
 toxicity, 84  
 fentanyls sold as replacement for in  
 European countries, 80–81  
 methamphetamine come-down  
 management, 206
- high anion gap metabolic acidosis  
 (HAGMA), associated with  
 GHB/GBL and 1,4-BD  
 intoxication, 42
- higher-intensity PSIs  
 derivation, 31  
 formal psychological treatment,  
 29–31, 156  
 residential treatment, 31  
 settings for delivery, 25–26  
 structured drug treatment, 27–29  
*see also* lower-intensity PSIs
- high-risk behaviours  
 fentanyl use and, 88  
 ketamine injecting related, 118  
 misuse of benzodiazepines  
 associated with, 67  
 synthetic cathinone related, 254  
*see also* high-risk sexual behaviours;  
 injecting
- high-risk sexual behaviours  
 amphetamine dependence and, 154  
 amphetamine-type stimulant use  
 and, 147–148  
 benzodiazepine NPS and, 69–70  
 CM and CBT interventions study for  
 methamphetamine users,  
 220  
 GHB use and, 39, 40  
 GHB/GBL use by MSM and, 40, 49  
 substance misuse and, 12
- HIV infection  
 amphetamine dependence and risk  
 of, 154  
 GHB/GBL  
 and ART, 44–45  
 relationship with, 40  
 injecting and risk of, 145  
 methamphetamine and, 208–209,  
 215  
 potential transmission as public  
 health risk, 53  
 prevalence in MSM who use  
 methamphetamine, 204  
 synthetic cathinone injection and,  
 250
- HIV services, as setting for lower-  
 intensity PSIs, 25
- homelessness  
 methamphetamine use and, 216  
 SCRA use associated with, 8, 304
- 5-HT<sub>2A</sub> receptors  
 effects of MDMA, 168  
 hallucinogens and, 271  
 ketamine activation, 102  
 second-generation antipsychotics  
 and, 314
- 5-HT<sub>2A</sub> antagonists, 152
- injecting  
 amphetamine-type stimulants  
 injection, risks associated  
 with, 147–148  
 deep-vein thrombosis risk, 145, 254  
 endocarditis risk, 145, 207, 254

- fentanyl, risks associated with, 88  
 and HIV infection, synthetic  
   cathinone, 250  
 HIV infection risk, 145, 250  
 ketamine, high-risk behaviours,  
   103–104, 118  
 methamphetamine, high-risk  
   behaviours, 204, 208,  
   209–210  
 stimulants  
   evidence of increase in, 144  
   harms associated with, 145  
 synthetic cathinones  
   high-risk behaviours, 243,  
   250–251  
   HIV and hepatitis C infection,  
   145, 250  
   risk of infection, 254  
 International Association of Forensic  
   Toxicologists (TIAFT), 10  
 The International Association of  
   Forensic Toxicologists  
   (TIAFT), 10  
 International Drug Control  
   Conventions, 6  
 International Standards for Treatment  
   of Drug Use Disorders, 13  
 Internet, role in the sale of drugs, 8–9  
  
 ketamine  
   acute toxicity, 106–107  
   clinical management, 111–112  
   diagnosis and assessment, 111  
   mortality, 110  
   poly-drug use, 109  
   symptoms/features, 107–108  
   analogues and derivatives of  
   ketamine and PCP, 107  
   chronic harms, 112–116  
   cognitive impairment, 115–116  
   depression, 116  
   diabetic ketoacidosis (DKA), 115  
   diagnosis and assessment, 116  
   gastrointestinal toxicity, 114–115  
   interaction with antiretroviral  
   medications, 115  
   memory impairment, 115–116  
   neurological effects, 116  
   psychological support, 117  
   social harms, 116  
   urinary tract damage, 113–114  
   management, 117–118  
   *see also* ketamine bladder.  
   dependence and withdrawal,  
   112–113  
   aftercare and support, 117  
   pharmacological interventions,  
   117  
   withdrawal symptoms, 113  
   effects  
     acute, 108  
     desired, 105–106  
     half-life, 102, 113  
     harm reduction advice, 119  
     high risk sexual and injecting  
     behaviours and, 103–104,  
     118  
     injecting, infection risk, 118  
     ‘keying’, 104  
     legal status, 102  
     medical uses, 101, 103  
     treatment of depression, 101, 103,  
     116  
     monitoring recommendations, 103  
     pharmacology, 102–103  
     poly-drug use, 106–107, 109  
     prevalence and patterns of use,  
     103–104  
     public health and safety, 118–119  
     research evidence, 102  
     risk of accidents and assaults, 119  
     routes/modes of ingestion and  
     dosing frequency, 104  
     self-medication uses, 106  
     street names, 102  
   ketamine bladder, 114  
   ‘keying’, 104, 246  
   khat, 240  
  
   legal control of NPS, changes in, 6  
   ‘legal highs’, 5  
   ketamine and PCP analogues, 105  
   LGBT (lesbian, gay, bisexual and  
   transgender) populations,  
   use of club drugs and NPS, 8  
   loss of consciousness/coma, 41  
   lower-intensity PSIs  
   brief interventions, 26–27  
   FRAMES model  
   example of, 28–29  
   brief interventions, FRAMES model  
   framework, 27  
   settings for delivery, 25  
   typical elements, 26  
   *see also* higher-intensity PSIs.  
   LSD (lysergic acid diethylamide)  
   clinical trials, 270  
   nitrous oxide interaction, 134  
   safety ratio, 276  
   lysergamides, pharmacology, 268  
  
   mapping tools, enhancing outcomes of  
   drug treatment with, 29  
   MDMA (ecstasy), 165  
   acute toxicity, 174–175  
   cardiac dysfunction, 178  
   clinical management, 180–181  
   diabetic ketoacidosis, 179  
   drug interactions, 179–180,  
   186–187  
   serotonin syndrome, 149, 152  
   hyperpyrexia/hyperthermia,  
   175–177  
   clinical management, 180  
   hyponatraemia, 177–178  
   gender differences, 177  
   intracranial haemorrhage, 179  
   liver failure, 179  
   poly-drug use, 171, 175, 178,  
   179–180, 186–187  
   serotonin syndrome, 149, 152  
   psychiatric presentations, 188  
   clinical management, 181  
   pulmonary harms, 178–179  
   serotonin syndrome, 149, 152  
   clinical management, 180  
   suicidal ideation and suicide,  
   178  
   symptoms/features, 175–176  
   adulteration with PMMA, 173–174  
   alternatives and variations, 166–167  
   analogues and NPS with similar  
   effects, 165  
   chronic harms, 181  
   cognitive deficits, 182  
   dependence and withdrawal,  
   183–185  
   treatment, 185–186  
   depression, treatment, 186  
   heart disease, 185  
   management, 185–186  
   neurotoxicity, 181–182  
   poly-drug use and, 183  
   psychiatric harms, 183  
   sleep problems, 185  
   vascular problems, 185  
   clinical use, 169–170  
   effects  
   desired, 172  
   unwanted, 173  
   gender differences, 175, 177  
   empathogenic effects, 165  
   fentanyls found in products sold as,  
   81  
   half-life, 169  
   hallucinogen co-ingestion, 273  
   harm reduction measures, 186–187  
   increase in average dose and  
   strength, 167–168  
   legal status, 168  
   mortality, 173–174  
   pharmacology, 168, 169  
   prevalence and patterns of  
   recreational use, 170–171  
   public health considerations,  
   186–187  
   research evidence, 168  
   routes/modes of ingestion and  
   dosing frequency, 171  
   *see also* benzofurans.

## Index

- MDPV (3,4-methylenedioxypropylvalerone), 240  
 acute toxicity, 249  
 effects, desired and unwanted, 248  
 legal status, 241  
 pharmacology, 242–243  
 routes/modes of ingestion and dosing frequency, 246  
 street names, 241  
 memory impairment  
 benzodiazepine-associated, 68  
 ketamine-associated, 107, 115–116  
 MDMA-associated, 173  
 methamphetamine-associated, 211  
 SCRA-associated, 306, 307  
 men who have sex with men (MSM)  
 amphetamine-type stimulant use, 148  
 benzodiazepine misuse, 68  
 CM and CBT interventions for methamphetamine dependence, 216, 220  
 frequent use of NPS by, 30  
 GHB and HIV antiretroviral therapy, 44–45  
 GHB/GBL use, 38  
 and potential high-risk sexual behaviour, 40, 49  
 healthcare recommendations, 40  
 ketamine use, 104, 106  
 mephedrone  
 injecting behaviours, 250  
 use, 7  
 methamphetamine, high-risk behaviours  
 injecting, 204, 208  
 sexual, 204–205, 208–209  
 methamphetamine use  
 and high-risk behaviours, 204–205, 208–209  
 prevalence and patterns of, 204–205  
 prevalence of drug use, 12  
 STIs, methamphetamine and GHB/GBL use, 40  
 synthetic cathinone use, 244–245  
 mental health  
 benzodiazepines and, 71  
 methamphetamine and, 213–215, 222  
 nitrous oxide and, 135–136  
 mental health services, as setting for lower-intensity PSIs, 25  
 4-MeO-PCP (methoxydine), 101–102, 105, 109, 112  
 mephedrone  
 acute toxicity, 249  
 diagnosis and assessment, 251  
 symptoms/features, 248–249, 250  
 comparison with benzofurans, 188  
 dependence potential, 252  
 driving and, 254  
 effects  
 desired, 247  
 unwanted, 247–248  
 emergence as a club drug, 170  
 legal status, 243  
 motives for using, 7  
 pharmacology, 242  
 potential danger to people with diabetes, 250  
 routes/modes of ingestion and dosing frequency, 246  
 street names, 241  
 withdrawal symptoms, 253  
 methadone, 88  
 methamphetamine and, 210  
 methamphetamine  
 acute harms, 206  
 cardiovascular and respiratory, 206–207  
 emergency hospital admissions, 210–211  
 hyperthermia, 207  
 management, 211  
 psychological, 208  
 psychosis, treatment, 211  
 renal and liver failure, 208  
 rhabdomyolysis, 207  
 symptoms/features of acute toxicity, 206  
 chronic harms  
 blood related, 213  
 brain imaging studies, 202, 215  
 cardiovascular, 212–213  
 cognitive, 215  
 co-morbidities with HIV, 215  
 dependence and withdrawal, *see* methamphetamine, dependence and withdrawal.  
 dermatological, 213  
 mental health/psychological effects, 213–215  
 interventions, 222  
 neurological, 213  
 ophthalmological, 213  
 Pott puffy tumour, 213  
 psychiatric, 203  
 pulmonary and respiratory, 213  
 clinical and other legitimate uses, 203  
 dependence and withdrawal, 211, 212  
 access to treatment, 221–222  
 aftercare and support, 222  
 contingency management, 216  
 diagnosis and assessment, 215  
 pharmacological interventions, 217, 219  
 psychosocial interventions, 215–217  
 social interventions, 216–217  
 treatment completion and effectiveness, 219–221  
 withdrawal symptoms, 212  
 drug interactions, 210  
 effects  
 desired, 205  
 unwanted, 205–206  
 half-life, 205  
 harm reduction measures, 222  
 high-risk behaviours  
 injecting, 208  
 sexual, 204–205, 208–209  
 legal status, 202  
 mortality, 206  
 pharmacology, 202–203  
 poly-drug use, 210  
 prevalence and patterns of use, 203–205  
 ‘clubbers’, 204  
 men who have sex with men, 204–205  
 population subgroups, 204–205  
 problem drug users, 204  
 pro-sexual effects, 148  
 research evidence, 202  
 routes/modes of ingestion and dosing frequency, 205  
 street names, 202  
 methoxetamine (MXE), 101  
 acute toxicity  
 clinical management, 111–112  
 mortality, 110  
 symptoms, 109  
 adulterants typically found in, 105  
 driving accidents associated with, 119  
 effects  
 desired, 106  
 unwanted, 106  
 introduced as alternative to ketamine, 101  
 legal status, 102  
 pharmaceutical potential, 103  
 pharmacology, 102–103  
 routes/modes of ingestion and dosing frequency, 104–105  
 street names, 102  
 urinary tract issues, 114  
 withdrawal symptoms, 113  
 methoxphenidine (MXP), 101, 102  
 acute toxicity, 110  
 3-methoxy-PCP (3-MeO-PCP), 101, 105  
 acute toxicity, 109  
 half-life, 109  
 methoxydine (4-MeO-PCP), 101–102, 105, 109, 112

- 2-methoxydiphenidine (2-MXP), 110  
 4-methoxyphenacyclidine, 111  
 3,4-methylenedioxy-  
   N-methylamphetamine, 165  
   *see also* MDMA (ecstasy).  
 3,4-methylenedioxy-  
   N-methylcathinone.  
 methylfentanyls, 80, 88  
 4-methylmethcathinone  
 4-methyl-N-ethcathinone (4-MEC),  
   240, 241, 242  
   street names, 241  
 methylphenidate  
   amphetamine dependence treatment  
     RCTs, 157  
   clinical uses, 147  
   treatment of amphetamine and  
   methamphetamine  
   dependence with, 217–218  
 4-methylthioamphetamine (4-MTA),  
   169  
 micro-dosing  
   definition, 271  
   hallucinogens, 271  
 mindfulness-based interventions  
   (MBIs), 32  
 mirtazapine, treatment of  
   amphetamine and  
   methamphetamine  
   dependence with, 217, 219  
 mislabelling of NPS, potential for  
   harm, 11  
 Misuse of Drugs Act (UK), 65  
 moclobemide, 179  
 modafinil, amphetamine dependence  
   treatment RCTs, 157  
 monoamine oxidase inhibitors  
   (MAOIs), association with  
   serotonin syndrome, 150,  
   152  
 morphine, comparison of fentanyl  
   with, 79, 81  
 mortality  
   amphetamine-type stimulants, 148  
   GHB/GBL, 40  
   methamphetamine, 206  
   PMMA, 177  
   synthetic cathinones, 251  
 motivational interviewing  
   effectiveness as substance use  
   intervention, 27  
   in structured drug treatment, 29  
   in WHO manual on brief  
   interventions, 27  
 mutual aid, tradition of in the  
   substance misuse field, 31  
 naloxone  
   fentanyl  
     overdose management, 87  
     toxicity treatment, 85–87  
   opioid overdose management, 90  
   opioids  
     overdose treatment, 85  
     role in preventing deaths  
       associated with, 85  
   potential for inhibition of nitrous  
   oxide analgesic effects, 131  
   respiratory depression management,  
     86  
   ‘take-home’ programmes (THN), 87  
 naltrexone, 157  
   amphetamine dependence treatment  
     RCT, 157  
   treatment of amphetamine and  
   methamphetamine  
   dependence with, 217, 218  
   treatment of ketamine withdrawal,  
     117  
   treatment of SCRA withdrawal, 314  
 naphyrone, 240, 241  
 narcolepsy  
   methamphetamine treatment, 203  
   treatment with amphetamines, 146  
   treatment with sodium salt of GHB,  
     38  
 Narcotics Anonymous (NA), 31  
 NBOMes (N-Benzylphenethylamines),  
   toxicity  
     clinical management, 279  
     symptoms, 277  
 NEPTUNE guidance  
   aims and guidance development,  
     1–2  
   development process, 3–4  
   literature review, 3  
   objectives, 1–2  
   reasons behind, 2  
   substances and drug groups covered,  
     3–4  
   target audience, 2  
   update, 3  
 neuroleptic malignant syndrome,  
   comparison with serotonin  
   syndrome, 152  
 new markets for drug acquisition, 8–9  
 night-time economy, club drugs and  
   NPS use, 8  
 nitrous oxide (N<sub>2</sub>O), 131–137  
   acute toxicity, 133–134  
     symptoms and features, 134  
   chronic harms, vitamin B12  
     deficiency, 131, 134, 135, 136  
     management, 136  
   clinical and other legitimate uses,  
     131  
   clinical management, 135  
   dependence and withdrawal, 135  
   diagnosis and assessment, 135  
   effects  
     desired, 132–133  
     gender differences debate,  
       133  
     unwanted, 133  
   harm reduction measures, 137  
   industrial applications, 131  
   likely cause of dissociative effects,  
     131  
   mental health harms, 135–136  
   mortality, 133  
   occupational exposure, concerns  
     around, 131, 132  
   pharmacology, 131  
   poly-drug use and drug interactions,  
     134  
   prevalence and patterns of  
     recreational use, 131–132  
   psychosocial and pharmacological  
   support, 136  
   public health considerations,  
     136–137  
   research evidence, 131  
   risk of confusion with other gases,  
     134  
   routes/modes of ingestion and  
     dosing frequency, 132  
   street names, 131, 135  
 N-methyl-D-aspartate (NMDA),  
   antagonists, 101–102, 109,  
   131  
 non-pharmaceutical fentanyls (NPF),  
   79  
 noradrenaline, effects of stimulant  
   agents on, 143  
 novel psychoactive substances (NPS)  
   changes in legal control, 6  
   classifying, 3–4  
   concept and background, 1  
   definition, 5–6  
   groupings, 5  
   growth and spread, 6–7  
   manufacture, 6  
   motives for using, 7  
   number of unique new substances  
   reported, 5–6  
   population groups most likely to use,  
     7–8  
   producers’ awareness of legal  
   frameworks, 5  
   targeting of at long-term/  
   problematic drug users, 8, 23,  
     78  
   users and contexts of use, 7  
 Novel Psychoactive Treatment UK  
   Network (NEPTUNE), aims  
   and guidance development,  
   *see* NEPTUNE guidance.  
 ocfentanil, 79, 84  
 opioid crisis, in North America, 78



## Index

- opioid medications, evidence of  
 misuse, 78
- opioid overdose  
 symptoms, 81  
 WHO guidelines, 85
- opioid related mortality,  
 benzodiazepines commonly  
 implicated in, 68
- opioids  
 acute intoxication, management, 90  
 adverse effects of intoxication, 89  
 availability and mode of use, 89  
 chemical structures, 89  
 chronic effects and dependence, 92  
 comparison with other NPS types,  
 78  
 dependence, management, 92  
 desired effects, 89  
 detected on Europe's drug market,  
 78  
 fentanyls, *see* fentanyls.  
 global public health threat, 78  
 intoxication, characteristics, 81  
 mortality, 92  
 non-fentanyl opioid NPS, 89  
 pharmacology, 89  
 poly-drug use and drug interactions,  
 84–85  
 reported to the EU Early Warning  
 System, 79  
 research evidence, 79  
 targeting of at long-term/  
 problematic drug users, 78
- overdose  
 amphetamine-associated, 148  
 benzodiazepine-associated, 69  
 fentanyl-associated, 82  
 comparison with heroin, 81, 84, 87  
 management with naloxone, 87  
 GHB/GBL-associated, 41  
 clinical management, 45–46  
 harm reduction measures, 46  
 naloxone and, 85, 87, 90  
 opioid-associated, 81  
 management with naloxone, 85,  
 90  
 symptoms, 81  
 risk of, *see* risk of overdose.  
 SCRA-associated, 305, 308
- 2-oxo-PCE, 110, 111
- oxytocin, 169, 172
- paranoia, 248
- Parkinson's disease  
 MDMA and relief from symptoms  
 of, 170  
 methamphetamine users' risk of  
 developing, 213  
 Parkinson-type symptoms, 250
- paroxetine
- MDMA and, 179  
 methamphetamine and, 210
- patterns of NPS use, parallels with  
 patterns of alcohol use, 23
- pentadrone  
 abuse liability, 240  
 street names, 241
- pentylone, 240, 245
- phenazepam, 66, 69, 302  
 half-life, 66  
 street names, 65
- phencyclidine (PCP), 101
- phenethylamines, 148  
 acute toxicity, clinical management,  
 279–280  
 adverse effects, 276–277  
 empathogenic effects, 165  
 pharmacology, 146, 268–269  
 routes/modes of ingestion and  
 dosing frequency, 273  
*see also* methamphetamine.
- $\alpha$ -PHP ( $\alpha$ -pyrrolidinohexanophenone),  
 240, 248  
 acute toxicity, 249
- pipradrols/piperidines, 144, 165
- placenta permeability, GHB/GBL, 38
- PMA (paramethoxyamphetamine)  
 acute toxicity, 174  
 adulteration of MDMA with, 173,  
 174  
 deaths associated with, 174  
 risks of co-ingestion, 179  
 toxicity, 148
- PMK (piperonyl methyl ketone), 170
- PMK (piperonyl methyl ketone),  
 PMK-glycidate, 170
- PMMA (p-methoxymethamphetamine)  
 acute toxicity, 174  
 adulteration of MDMA with,  
 173–174  
 mortality, 177  
 risks of co-ingestion, 179  
 serotonin syndrome, 177  
 toxicity, 148
- poisons centres, 2, 277
- Poland, 81
- poly-drug use  
 acute toxicity risk increased by, 9  
 amphetamine-type stimulants, 158  
 association with fatalities, 12  
 association with serotonin  
 syndrome, 149, 150  
 association with sexual risk  
 behaviours, 70  
 benzodiazepine misuse in context of,  
 67  
 fentanyls, 84–85  
 risks of, 82, 84  
 hallucinogens, 273
- ketamine, 106–107, 109  
 related high-risk behaviours, 118
- MDMA, 171, 175, 179–180, 183,  
 186–187  
 psychosis, 178  
 nitrous oxide, risk of death, 133  
 serotonin syndrome and, 149, 150,  
 152  
 synthetic cathinones, 245
- poly-drug use and drug interactions  
 GHB/GBL, 44  
 GHB/GBL, HIV antiretroviral  
 therapy, 44–45  
 MDMA, 179–180, 186–187  
 serotonin syndrome, 149, 152  
 methamphetamine, 210  
 nitrous oxide, 134  
 opioids, 84–85  
 synthetic cathinones, 251
- polysubstance use, 312, *see* poly-drug  
 use.
- population groups most likely to use  
 NPS  
 'clubbers' and night-time economy  
 users, 7–8  
 homeless people and prison inmates,  
 8  
 LGBT+ population, 8  
 men who have sex with men, 8  
 poly-drug users, 7  
 problem/long-term drug users, 8  
 'psychonauts', 8  
 young people, 7
- post-traumatic stress disorder (PTSD),  
 169, *see* PTSD (post-  
 traumatic stress disorder).
- Pott puffy tumour (PPT),  
 methamphetamine and, 213
- pregnancy, GHB/GBL detoxification  
 during, 50
- Priestley, Joseph, 131
- primary care  
 as setting for lower-intensity PSIs, 25  
 WHO manual on brief  
 interventions, 27
- prison populations  
 use of NPS, 8  
 use of SCRA, 304
- problem drug users  
 methamphetamine, prevalence and  
 patterns of use, 204  
 methamphetamine use, 204  
 synthetic cathinone use, 244  
 targeting of NPS at, 8, 23, 78
- prolactin, 169, 172
- psilocybin, clinical trials, 270
- psychonauts, use and understanding of  
 NPS, 8
- psychosis  
 amphetamine-associated, 154

- management, 157–158
- benzofuran-associated, 188
- GHB/GBL-associated, 42
- ketamine-associated, 116
- MDMA-associated, 178
- MDPV-associated, 249
- methamphetamine-associated, 205, 208, 210, 213, 214
  - treatment, 211
- phenethylamine-associated, 276
- $\alpha$ -PHP-associated, 249
- SCRA-associated, 306, 307, 309, 310, 311
- synthetic cathinone-associated, 250
- psychosocial interventions (PSIs)
  - adjustments to existing protocols, 23
  - available research, 22
  - EMCDDA principles, 22
  - evidence on effectiveness of, 22
  - evidence-based models, 32
    - motivational interviewing, 32
    - network and environmental therapies, 32
  - GHB/GBL, 50
  - higher-intensity PSIs
    - derivation, 31
    - residential treatment, 31
    - settings for delivery, 25–26
    - structured drug treatment, 27–29
  - identification of NPS use and severity, 23–25
  - indicators for referral, 25
  - lower-intensity PSIs
    - brief interventions, 26–27
    - example of FRAMES model, 28–29
    - framework, 27
    - settings for delivery, 25
    - typical elements, 26
  - methamphetamine dependence and withdrawal, 215–217
  - minimum recommended levels in selected settings, 26
  - mutual aid, 31
  - residential treatment, 31
  - social re-integration, 32
- psychosocial interventions,
  - methamphetamine, dependence and withdrawal, 215–217
- psychotherapy, MDMA-facilitated, 169–170
- PTSD (post-traumatic stress disorder), 169–170, 282
  - MDMA treatment, 281
  - therapeutic effects of hallucinogens, 274
- pyrovalerone, 243
- quinidine, 180
- recovery capital model, of substance misuse intervention, 24
- relapse prevention
  - CBT approach, 32
  - mindfulness-based approach, 156, 217
- residential treatment, indications for, 31
- respiratory depression, reversing with naloxone, 86
- responses to club drug and NPS use
  - adaptation of programmes for ‘established’ or ‘traditional’ drugs, 23
    - harm reduction strategies, 13–14
    - hospital emergency departments, 12
    - screening, identification and management of drug harms, 13
    - sexual health services, 12
    - substance misuse treatment services, 13
- rhabdomyolysis, benzodiazepine overdose and, 68
- riluzole, treatment of amphetamine and methamphetamine dependence with, 217
- risk of overdose
  - fentanyls, 82, 84
  - increased by injecting, 10, 82, 84, 88
  - increased by repeated administration of a drug, 9
  - MDMA, 169
  - PMA and PMMA mistaken for MDMA, 169
  - SCRAs, 301
- ritonavir, 44, 84, 102, 180, 210, 251
- safrole, 170
- schizophrenia, amphetamine-induced psychosis and, 154
- seizures
  - amphetamine, 148–149
  - anti-psychotic medication, 157
  - benzodiazepine, 69, 71
  - GHB/GBL, 44, 48
  - hallucinogenic drugs, 276, 277
  - ketamine, 108
  - MDMA and drugs with similar effects, 173, 174–176, 177
  - mephedrone and other synthetic cathinones, 249
  - methamphetamine, 206, 213
  - methoxphenidine, 110
  - nitrous oxide, 134
  - opioid NPS, 91
  - paediatric, exposure to synthetic cathinones and, 249
  - phenethylamine, 276
  - PMA/PMMA, 174
  - SCRA, 306, 307, 308, 309, 310, 311, 312, 313, 314
    - serotonin syndrome, 150
  - self-medication
    - hallucinogens, 274
    - ketamine, 106
  - serotonin, effects of stimulant agents on, 143
  - serotonin syndrome
    - amphetamine-type stimulants-associated, 149–150, 153, 158
      - poly-drug use and, 158
    - comparison with neuroleptic malignant syndrome, 152
    - diagnosis, 151–152
    - fentanyl-associated, 84
    - hallucinogen-associated, 275, 277
    - 5-HT<sub>2A</sub> antagonists treatment, 152
    - management, 151–153
    - MAOI-associated, 150, 152
    - MAOIs and, 150, 152
    - MDMA, 149, 152, 177
    - MDMA-associated
      - clinical management, 180
      - fatal, 173, 177
    - methamphetamine co-ingestion and, 210
    - phenethylamine-associated, 279
    - poly-drug use and, 149, 150, 152
    - risk of convulsions, 152
      - see also seizures.
    - SCRA-associated, 308
    - symptoms/features, 149–150, 187
    - synthetic cathinone-associated, 249, 252
    - therapeutic drugs, 150
    - treatment, 152
  - serotonergic agents, risks of using fentanyl with, 84
  - sertraline, treatment of amphetamine and methamphetamine dependence with, 219
  - sexual assault
    - GHB implicated in, 38
    - GHB/GBL’s association with, 53
    - ketamine use and the risk of, 119
  - sexual behaviours, high risk, 30, see high-risk sexual behaviours.
  - sexual health services
    - prevalence of drug use among patients of, 12
    - as setting for higher-intensity PSIs, 26
    - as setting for lower-intensity PSIs, 25
  - sexualised drug use, effectiveness of combined interventions, 30–31

## Index

- sexually transmitted infections (STIs),  
 association with  
 methamphetamine and  
 GHB/GBL use, 40
- sildenafil (Viagra), 39, 204, 209
- Single Convention on Narcotic Drugs  
 (1961), 5
- 'skunk', 309
- 'slamming', 251
- SMART groups, 31
- social behaviour network therapy  
 (SBNT), 32
- social media, acquisition of drugs and  
 NPS through, 9
- social re-integration, 32
- sodium oxybate, treatment of  
 narcolepsy, 38
- 'speedballing', 84
- SSRIs (selective serotonin reuptake  
 inhibitors), association with  
 serotonin syndrome, 150
- stepped care approach, principles, 23
- stimulants  
 dependence, 155–158  
 aftercare and support, 158  
 amphetamine-induced psychosis,  
 management, 157–158  
 characteristic features, 155  
 pharmacological interventions,  
 157  
 psychosocial interventions,  
 155–157  
 psychosocial interventions,  
 Cochrane review, 155  
 stepped care for amphetamine-  
 type stimulants users,  
 155–156  
 gender differences in responses to,  
 157  
 injecting  
 harms associated with, 145  
 increase in, 144  
 pharmacology, 143  
 prevalence and patterns of use, 147  
 prevalence and types of NPS  
 globally, 144  
 regional variations, 147  
 stimulant NPS in Europe, 143–145  
*see also* amphetamine-type  
 stimulants (ATS).
- street names  
 benzodiazepines, 65  
 ketamine, 102  
 MDPV, 241  
 4-MEC, 241  
 mephedrone, 241  
 methamphetamine, 202  
 methoxetamine, 102  
 nitrous oxide, 131, 135  
 pentedrone, 241  
 phenazepam, 65  
 SCRA, 299  
 synthetic cathinones, 240
- STRIDA Project, 110
- structured drug treatment, minimum  
 requirements, 29
- substance misuse treatment services,  
 responses to club drug and  
 NPS use, 13
- substituted phenylethylamines, 144
- suicidal ideation and suicide, MDMA-  
 associated, 178
- suicidal ideation/thoughts  
 association with benzodiazepine use  
 in opioid use disorders, 68  
 MDMA-associated, 178  
 mephedrone-associated, 250
- suicide  
 amphetamine dependence and, 154  
 attempted, methoxetamine-  
 associated, 109  
 benzodiazepine as risk factor, 71  
 GHB-associated, 40  
 LSD-associated, 279  
 methamphetamine-associated, 206,  
 208, 210
- symptom rebound, benzodiazepine-  
 associated, 70
- synthetic cannabinoid receptor  
 agonists (SCRAs)  
 acute harms, 305–313  
 adulterant-associated, 307  
 cardiovascular, 309  
 diagnosis and assessment, 312  
 gastrointestinal/renal, 310  
 multiple organ failure, 310  
 neurological, 308, 309–310  
 physiological, 309–310  
 presentations for treatment for  
 acute intoxication, 310–312  
 psychological, 307–309  
 psychosis, 309  
 toxicity  
 clinical management, 312–313  
 symptoms/features of, 305–308  
 association with homeless people  
 and with prison populations,  
 8  
 available products, 301–302  
 chronic harms, 313–315  
 dependence and withdrawal,  
 313–314  
 clinical management, 314  
 support and aftercare, 315  
 management, 314–315  
 other, 314  
 clinical and other legitimate uses,  
 302  
 effects  
 desired, 303–304  
 unwanted, 304–305  
 fatal toxicity index, 9  
 harms associated with newer  
 generations of, 11  
 legal status, 299, 301  
 mortality, 305  
 pharmacology, 299–301  
 prevalence and patterns of use,  
 302–303  
 public safety considerations and  
 harm reduction measures,  
 315  
 research evidence, 299  
 routes/modes of ingestion and  
 dosing frequency, 303  
 street names, 299  
 targeting of at long-term/  
 problematic drug users,  
 23  
 use by homeless people and prison  
 inmates, 304
- synthetic cannabinoids  
 HPPD and, 280  
 similarity to benzodiazepine NPS,  
 66, 280  
*see also* synthetic cannabinoid  
 receptor agonists (SCRAs).
- synthetic cathinones, 144, 240  
 acute harms, 249, 251  
 high-risk injecting and sexual  
 behaviour, 250–251  
 mortality, 251  
 poly-drug use and drug  
 interaction, 251  
 toxicity, 248–249
- acute toxicity  
 diagnosis and assessment, 251  
 management, 252  
 MDPV, 249  
 mephedrone, 248–249  
 α-PHP, 249  
 symptoms/features, 249–250  
 treatment outcome, 252
- chronic harms  
 clinical management, 254  
 dependence and withdrawal,  
 252–254  
 clinical management, 254  
 risk of infection, 254  
 clinical uses, 243  
 comparability to traditional drugs of  
 abuse, 242
- effects  
 desired, 245–247  
 MDPV, 248  
 mephedrone, 247–248  
 α-PHP, 248  
 unwanted, 247  
 empathogenic effects, 165  
 half-life, 245

- harms associated with newer generations of, 11
- high-risk injecting behaviour, 243, 250–251
- legal status, 241
- natural analogue, 240
- pharmacology, 241–243
- combination products, 243
- MDPV, 242–243
- mephedrone, 242
- prescribed medications containing, 240
- prevalence and patterns of
- recreational use, 243–245
- men who have sex with men (MSM), 244–245
- poly-drug use, 245
- population sub-groups, 244–245
- public health crisis associations, 243
- public safety and harm reduction measures, 254
- pyrovalerones, 240
- research evidence, 241
- routes/modes of ingestion and dosing frequency, 245–246
- MDPV, 246
- mephedrone, 246
- second and third generations, 240
- street names, 240
- see also* bupropion; MDPV (3,4-methylenedioxypropylvalerone); mephedrone; mephedrone; pentedrone.
- synthetic opioids
- reported rise in deaths related to, 78
- worldwide public health risk, 78
- see also* fentanyl; opioids.
- tachyphylaxis, hallucinogens, 272, 280
- testing for club drugs and NPS, limitations of, 11–12
- THC (tetrahydrocannabinol), 300
- thioridazine, 179
- topiramate, treatment of amphetamine and methamphetamine dependence with, 217–218, 219
- toxicity, definition, 9
- tramadol, 84, 150, 245
- trauma informed interventions, need for research, 23
- tremor
- benzodiazepine treatment for, 152
- serotonin syndrome and, 151
- see also* seizures.
- tryptamines, 144
- adverse effects, 277–278
- pharmacology, 268
- routes/modes of ingestion and dosing frequency, 272
- urological/urinary problems
- GHB/GBL-associated, 42
- ketamine-associated, 107, 113–114
- management, 117–118
- opioid-associated, 81
- Viagra, 39, 204, 209
- vitamin B12 deficiency, nitrous oxide-associated, 131, 134, 135, 136
- management, 136
- ‘wooden chest’, fentanyl-associated, 82
- World Drug Report
- on non-medical use of benzodiazepines, 67
- on number of NPS present on the market, 6
- on stimulants, 147
- on targeting of new psychoactive substances at long-term/problematic drug users, 78
- World Health Organization (WHO), manual on brief interventions, 27
- young people, use of club drugs and NPS, 7
- ‘zombie’-like behaviours associated with SCRA, 301, 306